Inder Mehmi CV Bio 300px

Inder Mehmi, M.D.

  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Medical Oncologist

Inder Mehmi, M.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Breast Cancer
  • Melanoma
Other Languages Spoken
  • Panjabi
  • Hindi
Inder Mehmi, M.D., specializes in the treatment of breast cancer and melanoma. Patients describe him as a “wonderful doctor,” “informative,” “pleasant” and “very trustworthy.”
 
Raised in India, Dr. Mehmi moved to California where he received his undergraduate degree at University of California Davis, followed by medical training at Ross University School of Medicine in Dominica, West Indies. He completed his residency at West Virginia School of Medicine/J.W. Ruby Memorial Hospital in Morgantown, West Virginia, and a fellowship in medical oncology at Edwards Comprehensive Cancer Center/Cabell Huntington Hospital in Huntington, West Virginia.
 
While in West Virginia, Dr. Mehmi was selected to serve on the National Cancer Institute Central Institutional Review Board. The CIRB is dedicated to protecting the rights and welfare of participants in cancer clinical trials.
 
As a researcher, Dr. Mehmi is focused on applying the latest immunotherapy advances to battle solid tumors.
  • 2019-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Simi Valley and Thousand Oaks, CA
  • 2015-2018, Assistant Professor, Hematology/Oncology, Robert C. Byrd Health Science Center, West Virginia University, Morgantown, WV

Simi Valley

City of Hope Simi Valley, 1157 Swallow Lane, Simi Valley, CA, 93065

Get Directions

Phone :  805-527-2770

Thousand Oaks

425 Haaland Drive, Suite 101, Thousand Oaks, CA, 91361

Get Directions

Phone :  805-496-2949

Degrees

  • 2007, Doctor of Medicine, Hematology/Oncology, Ross University School of Medicine, Dominica, West Indies
  • 1998, Bachelor, Molecular and Cellular Biology, University of California Davis, Davis, CA

Fellowship

  • 2013-2015, Fellowship, Medical Oncology, Edwards School of Medicine/Marshall University, Huntington, WV

Residency

  • 2007-2011, Resident, Medicine, Virginia School of Medicine/Ruby Memorial Hospital Morgantown, West Virginia
  • American Board of Internal Medicine, Medical Oncology
  • American Board of Internal Medicine, Internal Medicine
  • West Virginia Substance Registration
  • ECFMG Certification
  • DEA Registration: Active
  • ACLS/BLS Certified, Renewal Pending
Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral Sclerouveitis Secondary to Nivolumab Therapy for Metastatic Melanoma: A Report of a Case. Int J Ophthalmol. 2017 Jul. 18, 10 (7), 1183-1186

Khelfa Y, Alsharedi M, Mehmi I, Raufi A, Arrington A, Lebowicz Y, Pacioles T. Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case report of Rare Tumor with Literature Review. Journal of Gastroenterology Cancer. 2015 November.

Mozayen M, Farouq MF, Mehmi I, W. Gress TW, Tirona MT. Delaying Chemotherapy in the Treatment of Stage IV Non-Small Cell Lung Cancer Does Not adversely affect Survival Outcome. WVMJ, www.wvsma.org

Salisbury T, Tomblin T, Primerano D, Boskovic G, Fan J, Mehmi I, Fletcher J, Santanam N Hurn, E, Morris G, Denvvir J. Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells. Biochem Pharmacol. 2014 Oct 1; 91(3):390-9.

Tsai MS, Bogart D, Li P, Mehmi I, Lupu R. Expression and Regulation of Cyr61 in Human Breast Cancer Cell Lines. Oncogene. 2002 January 31; 21(6):964-73.

Atlas E, Cardillo M, Mehmi I, Zahedkaragaran H, Tang C, Lupu R. Heregulin is Sufficient for the Promotion of Tumorigenicity and Metastasis of Breast Cancer Cells in vivo. Mol Cancer Res 2003 Jan; 1(3):165-75.

Tsai MS, Taylor-Shamon L, Mehmi I, Tang C, Cardillo M, Lupu R. Blockage of Heregulin Expression Inhibits Tumorigenicity and Metastasis of Breast Cancer. Oncogene 2003 Feb 6; 22(5):761-8.

Atlas E, Bojanowski K, Mehmi I, Lupu R. A Deletion Mutant of Heregulin Increases the Sensitivity of Breast Cancer Cells to Chemotherapywithout Promoting Tumorigenicity. Oncogene. Oncogene. 2003 May 29; 22(22):3441-51.

Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endo Relat Cancer. 2003 Jun;10(2):141-52

Lupu R, Mehmi I, Atlas E, Tsai MS, Pisha E, Oketch-Rabah HA, Nuntanakorn P, Kennelly E, Kronenberg F. Black cohosh (Cimicifuga racemosa) does not Contain Estrogenic Activity and does not promote breast cancer cell growth. Int J Oncol. 2003 Nov; 23(5):1407-12.

Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Onocl. 2004 Mar; 24(3)591-608.

Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor associated fatty acid synthase activity antagonizes estradiol- and tamoxifen- induced agonist trasactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene. 2004 Jun 17; 23(28):2945-58.

Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogene antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol. 2004 Jun: 24(6):1369-83.

Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid santhase (FAS) suppresses HER2/new (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29): 10715- 20.

Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog. 2004 Nov; 41(3):164-78.

Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene. 2005 Jan 27; 24(5):761-79.

Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatininduced genotoxic damage. Int J Oncol. 2005 Mar; 26(3):649-59.

Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006 Aug 10; 24(23):3735-46.
 

Abstracts:

Ribas A, Milhem M, Hoimes C, Amin A, Mehmi I, Lao C, Conry R, Shaheen M, Jang S, Salama A, Deva S, Medina T, Schmidt EV, Leung A, Xing B, Janseen R, Long G. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD1 therapy. 2018 ASCO Annual Meeting, June 1-5, 2018, Chicago, IL. Status Accpeted.

Schwartzberg L, Yang Z, Peguero J, Agajanian R, Bharadwaj J, Restrepo A, Hlalah O, Mehmi I, Bhat G, Cobb P, ADVANCE Study Group. Eflapegrastim is safe and effective in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a Phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial). 2018 ASCO Annual Meeting, June 1-5, 2018, Chicago, IL. Status Accpeted for publication.

Schwartzberg L, Yang Z, Peguero J, Agajanian R, Bharadwaj J, Restrepo A, Hlalah O, Mehmi I, Bhat G, Cobb P, ADVANCE Study Group. Eflapegrastim is safe and effective in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a Phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial). MASCC/ISOO, Annual meeting 2018, Vienna, Austria. Status Accepted for podium presentation.

Mehmi I, Hill J. Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma. 2018 ASCO Annual Meeting, June 1-5, 2018, Chicago, IL. Status Accpeted for publication.

Milhem M, Gonzales R, Medine T, Kirkwood JM, Buchbinder E, Mehmi I, Niu J, Shaheen M, Weight R, Margolin K, Luke J, Morris A, Mauro D, Krieg AM, Ribas A. CT144-Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pebrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. Oral Presentation, AACR Annual Meeting, April 14-18, 2018 Chicago, IL, USA.

Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral Sclerouveitis Secondary to Nivolumab Therapy for Metastatic Melanoma. American Academy of Ophthalmology, 2016

Mehmi I, Bhavsar I, Griswald D, Gress T, Yehuda Lebowicz Y. Role of Tumor Infiltrating Lymphocytes in Small Cell Lung Cancer. 16th World Conference on Lung Cancer, Internation Association for the Study of Lung Cancer, Sept 6-9, 2015. Denver, CO.

Mehmi I, Salisbury T. Stabilization of Cyclin D1 with PDTC leads to MDA-MB 231 Cell death. 20th Annual NCCN Conference, Hollywood FL, March 12th 2015. downstream effector of heregulin, protects breast cancer cells from paclitaxel-induced cell

Mozayen M, Alsharedi MF, Mehmi I, Gress TW, Tirona MT. Effect of delaying chemotherapy on survival outcomes in the treatment of stage IV non-small cell lung cancer. e19092, 2014 ASCO Annual Meeting, Chicago, IL

Mehmi I, Lupu R. Breast Cancer Strategies for Therapeutic Intervention. International Journal of Molecular Medicine, Crete, Greece. October 18, 2001

Mehmi I, Kennelly E, Atlas E, Tsai MS, Shamon-Taylor L, Nakanishi K, Kronenberg F, Lupu R. Copitis chinenses contains antiestrogen-like compounds that may have chemotherapeutic and chemopreventive value. International Scientific Conference on Complementary, Alternative, and Integrative Medicine Research, Boston, MA. April 12, 2002.

Oketch-Rabah H, Mehmi I, Tsai MS, Atlas E, Kennelly E, Nuntanakorn P, Kronenberg F, Lupu R. Black cohosh (Cimicifuga racemosa) does not contain estrogenic activity. International Scientific Conference on Complementary, Alternative, and Integrative Medicine Research, Boston, MA. April 12, 2002.

Atlas E, Mehmi I, White K, Lupu R. N-terminal deletion of the heregulin protein affects anchorage-independent growth and E2-dependence. 93rd Annual Meeting of American Association for Cancer Research, San Francisco, CA. April 6-12, 2002

Tsai MS, Mehmi I, Bogart D, Castaneda J, Lupu R. Cyr61 induces breast tumorigenicity and promotes breast cancer progression through regulation of the MAPK and AKT signaling pathways. 93rd Annual Meeting of American Association for Cancer Research San Francisco, CA. April 6-12, 2002.

Menendez J, Mehmi I, Atlas E, Tsai MS, Lupu R. The angiogenic factor CYR61, a death through integrin alphaVbeta3. 14th EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics, Frankfurt, Germany. November 20-22, 2002.
  • 2015-Present, Present American College of Physicians
  • 2015-Present, American Society of Clinical Oncology
  • 2015-Present, West Virginia Oncology Society
  • 2017-Present, ASCO’s Volunteer Corps
  • 2017-Present, Journal Peer Reviewer of ASCO journals
  • 2017-Present, NCI CIRB LPE, board member
Back To Top